The role of AI in oncology: present applications and future horizons

Artificial intelligence (AI) offers a powerful means to accelerate precision oncology by individualizing care in an era of rapidly evolving treatment paradigms. However, there is limited regulatory oversights for safe clinical implementation of AI, and concerns surrounding data bias, ownership, and privacy have hindered broad integration into healthcare practice. In this perspective, we offer a forward-looking roadmap for the dissemination of AI in oncology. We discuss the role for AI in guiding biomarker-driven patient selection for clinical trials and in facilitating both personalized drug selection and de novo drug design by the potential to predict therapeutic response. We highlight the capabilities, and current limitations, of AI to inform realistic pathways for practical implementation.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-04-14
DOI
https://doi.org/10.1038/s41698-026-01408-y
Primary Topic
Artificial Intelligence in Healthcare and Education
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of AI in oncology: present applications and future horizons

Arun Rai, Nirmish Singla, Aidan Weitzner
npj Precision Oncology
Artificial Intelligence in Healthcare and Education
article

The role of AI in oncology: present applications and future horizons

Arun Rai, Nirmish Singla, Aidan Weitzner
article en

Abstract

Artificial intelligence (AI) offers a powerful means to accelerate precision oncology by individualizing care in an era of rapidly evolving treatment paradigms. However, there is limited regulatory oversights for safe clinical implementation of AI, and concerns surrounding data bias, ownership, and privacy have hindered broad integration into healthcare practice. In this perspective, we offer a forward-looking roadmap for the dissemination of AI in oncology. We discuss the role for AI in guiding biomarker-driven patient selection for clinical trials and in facilitating both personalized drug selection and de novo drug design by the potential to predict therapeutic response. We highlight the capabilities, and current limitations, of AI to inform realistic pathways for practical implementation.

npj Precision Oncology
Johns Hopkins University (US), Johns Hopkins Medicine (US)
Openalex Percentile: Top 10%
Artificial Intelligence in Healthcare and Education
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.